Strut Health: a reading note

Super Strut is a particular combination

Strut's Super Strut page describes a compounded dissolvable tablet containing tadalafil, vardenafil, apomorphine and oxytocin. The brand's wider sexual-health catalog also includes other medicines. This profile keeps the Super Strut offer separate so its formula and subscription are not inadvertently applied to every Strut product. [Super Strut] [Catalog]

Although the marketing uses four-in-one language, the formula is not the same as CoreAge 4Play or BlueChew GOLD. Ingredient identity and prescription strength matter more than the number in a headline. Do not compare the products as interchangeable doses or assume their instructions match.

Read all three price tiers

The page lists ten tablets as a 30-day supply at $79 for the low strength, $89 for medium and $99 for high. It advertises auto-refill, physician consultations, follow-ups and shipping within the offer. Final treatment and price depend on the clinical assessment. A listed supply period does not determine an individual's frequency of use.

The page also says cancellation is available at any time. Confirm how that affects an order already being processed, the cutoff for the next charge and any refund conditions. We have not tested those arrangements. The billing article explains why the recurring charge belongs in the initial comparison.

Timing language remains a provider claim

Strut makes onset, duration and intimacy-related claims on the product page. This publication does not treat them as independently established outcomes for the compound. FDA explains that compounded drugs are not approved and that the category differs from approved generics. Ask why a compounded option meets your medical need and what evidence supports the proposed preparation. [FDA]

Obtain the dispensing pharmacy's name and label-specific instructions, including storage and the beyond-use date. Our claim-reading guide provides the wider context. This profile adds a different advertised formula to the directory; it does not establish superior clinical performance or report a first-hand treatment experience.